swelling; redness; appears like a rash; inflamed; hot to touch; pain in the injection site; This spontaneous case was reported by a health care professional and describes the occurrence of VACCINATION SITE PAIN (pain in the injection site), INFLAMMATION (inflamed), VACCINATION SITE WARMTH (hot to touch), INJECTION SITE SWELLING (swelling) and INJECTION SITE ERYTHEMA (redness) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history information was reported.  Concomitant products included ASCORBIC ACID, ERGOCALCIFEROL, NICOTINAMIDE, RETINOL PALMITATE, RIBOFLAVIN, THIAMINE MONONITRATE (MULTIVITAMIN 6), VITAMIN C [ASCORBIC ACID], VITAMIN D [VITAMIN D NOS] and SPIRONOLACTONE for an unknown indication.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced VACCINATION SITE PAIN (pain in the injection site). On 21-Jan-2021, the patient experienced INFLAMMATION (inflamed) and VACCINATION SITE WARMTH (hot to touch). On 24-Jan-2021, the patient experienced INJECTION SITE SWELLING (swelling), INJECTION SITE ERYTHEMA (redness) and RASH (appears like a rash). At the time of the report, VACCINATION SITE PAIN (pain in the injection site), INFLAMMATION (inflamed), VACCINATION SITE WARMTH (hot to touch), INJECTION SITE SWELLING (swelling), INJECTION SITE ERYTHEMA (redness) and RASH (appears like a rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment details were reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 25-Jan-2021 and was forwarded to Moderna on 25-Jan-2021.    This spontaneous case was reported by a health care professional and describes the occurrence of VACCINATION SITE PAIN (pain in the injection site), INFLAMMATION (inflamed), VACCINATION SITE WARMTH (hot to touch), INJECTION SITE SWELLING (swelling) and INJECTION SITE ERYTHEMA (redness) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history information was reported.  Concomitant products included ASCORBIC ACID, ERGOCALCIFEROL, NICOTINAMIDE, RETINOL PALMITATE, RIBOFLAVIN, THIAMINE MONONITRATE (MULTIVITAMIN 6), VITAMIN C [ASCORBIC ACID], VITAMIN D [VITAMIN D NOS] and SPIRONOLACTONE for an unknown indication.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced VACCINATION SITE PAIN (pain in the injection site). On 21-Jan-2021, the patient experienced INFLAMMATION (inflamed) and VACCINATION SITE WARMTH (hot to touch). On 24-Jan-2021, the patient experienced INJECTION SITE SWELLING (swelling), INJECTION SITE ERYTHEMA (redness) and RASH (appears like a rash). At the time of the report, VACCINATION SITE PAIN (pain in the injection site), INFLAMMATION (inflamed), VACCINATION SITE WARMTH (hot to touch), INJECTION SITE SWELLING (swelling), INJECTION SITE ERYTHEMA (redness) and RASH (appears like a rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment details were reported.